November 30, 2017

Jan Tkac and Tomas Bertok – Scientists of the year award winners - establish Glycanostics to bring their revolutionary innovation to cancer diagnostics market

Glycanostics is an innovative start-up company established in 2017 to bring its revolutionary cancer diagnostics products to the US and EU markets. The company was founded by two remarkable scientists PhD Jan Tkac and PhD Tomas Bertok who got international recognition for their scientific works, prestigious grants and awards winners such as Scientists of the year (Slovakia), European Research Council (ERC) Consolidator grant, Marie Skłodowska-Curie actions ITN, Qatar National Research Fund.

 The mission of the project is to develop glycan-based reliable, accurate, quantitative, affordable and less-invasive tests for cancer diagnostics which could save thousands of patients from misdiagnosis in early stages of the disease. The Report on the implementation of the Council Recommendation on cancer screening concludes that nearly 50% of cancer deaths can be avoided. Glycanostics first product – Prostate Cancer DX kit - can provide a reliable and precise early cancer diagnosis, avoiding unnecessary biopsies and potentially aggressive treatment.

“Based on “glycocode deciphering“ our test is done by the analysis of glycan changes on specific proteins like PSA directly in human serum. Being much more precise than currently existing methods our innovative approach is designed to help doctors to make a proper decision about the correct need to perform a biopsy or a re-biopsy,” 

comment PhD Jan Tkac and PhD Tomas Bertok, founders of Glycanostics Ltd. 

The company plans to introduce the first product – Prostate Cancer DX kit - already in 2019 as a second opinion test helpful to currently existing but less precise PSA and biopsy tests.

Glycanostics Ltd. Brand

Other News

June 22, 2021

Glycanostics meet the President of the EC Mrs. Ursula von der Leyen

On Monday, June, 21st our CEO Eva Kovacova (on the right) together with CSO Jan Tkac (on the left) had a great honour to introduce the company Glycanostics to the President of the EC Mrs. Ursula von der Leyen, our Prime Minister Mr. Eduard Heger and Vice-President of the EC Mr. Maros Sefcovic. As one out of seven selected innovative companies, we presented our highly accurate, non-invasive, and early-stage cancer diagnostics that can help save the lives of millions of people worldwide.

October 18, 2019

A highly-prestigious award for a Glycanostics co-founder

ESET launched a prestigious ESET Science Award for exceptional scientists

October 3, 2019

International Patent Application No. PCT/EP2019/057386

Means and methods for glycoprofiling of a protein

August 31, 2019

Glycanostics succesfully finished Horizon 2020 SME Instrument 1 Grant

Glycanostics successfully finished the first phase of SME Instrument

December 10, 2018

Glycanostics Wins Horizon 2020 Grant

After receiving the prestigious “Seal of Excellence” on October 23, the next submission to the Horizon 2020 Programme, won a € 50 000 grant.

October 27, 2018

Glycanostics Receives the Prestigious Horizon 2020 “Seal of Excellence”

This project received the highest scores for its proposal in the extremely competitive evaluation process.

October 24, 2018

Glycanostics Wins TOP-6 Best Startups in Central Europe

Glycanostics was chosen as a finalist in the Grand Finale with five other remarkable startups.

August 14, 2018

Glycanostics Applies for Innovation-Securing Patent

The application covering Glycanostics' diagnostic method is currently filed in two patent offices in Europe and Luxemburg.

July 27, 2018

Glycanostics wins the European Research Council Grant

Glycanoctics innovations are again supported and highly ranked by leading industry experts. This time the company won the European Research Council (ERC) Proof of Concept Grant.

June 14, 2018

Glycanostics Takes 3rd Place in Vodafone’s Idea of The Year Competition

The competition's objectives are to actively support innovative projects with high market potential

May 1, 2018

Glycanostics PCa DX kit showed 95+% accuracy on the pre-clinical validation

In April 2018 the technology validation was successfully completed indicating a great potential of Glycanostics innovative products for prostate cancer (PCa) diagnostics.